Yang Dae Yul, Ko Kyungtae, Lee Seong Ho, Moon Du Geon, Kim Jong Wook, Lee Won Ki
Department of Urology, College of Medicine, Hallym University, Chuncheon, Korea.
Department of Urology, College of Medicine, Korea University, Seoul, Korea.
Asian J Androl. 2018 Jan-Feb;20(1):80-84. doi: 10.4103/aja.aja_1_17.
There is no safe and effective standard method for glans penis augmentation. Furthermore, there has been scant research on glans penis augmentation due to a poor understanding of glans anatomy, technical difficulty, and a lack of suitable substances for augmentation. Cross-linked dextran gel is a newly developed filler for soft-tissue augmentation. We evaluated the efficacy and safety of using a novel technique to inject cross-linked dextran gel for glans penis augmentation during a 24-week follow-up study. This prospective, single-arm, multicenter study enrolled twenty healthy adult men who underwent glans penis augmentation between June and August 2013. Cross-linked dextran gel was injected into the glans penis using a simple and easy technique. The sizes of the glans penis and individual satisfaction were assessed. Any adverse event was also reported. A total of 18 individuals were analyzed; two of them were lost to follow-up. The mean procedure time and injected volume were about 30 min and 6.6 ± 0.9 ml, respectively. The mean surface areas of the glans at baseline and 24 weeks were 20.0 ± 3.5 cm2 and 33.6 ± 5.4 cm2 , respectively, representing a mean increase of 68.7% ± 14.0% (P < 0.001). Sixteen individuals (88.9%) were satisfied with the outcomes, and none were dissatisfied. There were no serious adverse events during the study. Cross-linked dextran gel injection for glans penis augmentation was easy and showed a significant augmentative effect on the glans penis, good durability, and was well tolerated without serious adverse events. Therefore, cross-linked dextran gel injection may be an effective, new technique for glans penis augmentation.
目前尚无安全有效的标准阴茎龟头增大方法。此外，由于对龟头解剖结构认识不足、技术难度大以及缺乏合适的增大物质，关于阴茎龟头增大的研究很少。交联葡聚糖凝胶是一种新开发的软组织填充剂。在一项为期24周的随访研究中，我们评估了使用新技术注射交联葡聚糖凝胶进行阴茎龟头增大的疗效和安全性。这项前瞻性、单臂、多中心研究招募了20名健康成年男性，他们于2013年6月至8月期间接受了阴茎龟头增大手术。采用简单易行的技术将交联葡聚糖凝胶注入阴茎龟头。评估阴茎龟头的大小和个体满意度。同时报告任何不良事件。共分析了18例患者，其中2例失访。平均手术时间和注射量分别约为30分钟和6.6±0.9毫升。基线时和24周时龟头的平均表面积分别为20.0±3.5平方厘米和33.6±5.4平方厘米，平均增加68.7%±14.0%（P<0.001）。16例患者（88.9%）对结果满意，无不满意者。研究期间未发生严重不良事件。注射交联葡聚糖凝胶进行阴茎龟头增大操作简便，对阴茎龟头有显著增大效果，耐久性好，耐受性良好，无严重不良事件。因此，注射交联葡聚糖凝胶可能是一种有效的阴茎龟头增大新技术。
